Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?

BACKGROUND: More than 50% of hepatitis C viruses (HCV)-infected patients do not respond to the classical Interferon (IFN)/Ribavirin (RBV) combination therapy. The aim of this study was to evaluate the efficacy of retreatment with Peg-Interferon alpha-2b (PEG-IFN alpha-2b) plus RBV, in patients with...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Gonçales, Fernando L, Moma, Camila A, Vigani, Aline G, Angerami, Adriana FCF, Gonçales, Eduardo SL, Tozzo, Raquel, Pavan, Maria HP, Gonçales, Neiva SL
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2010
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2912909/
https://ncbi.nlm.nih.gov/pubmed/20646277
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2334-10-212
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky